{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:16:30Z","timestamp":1790957790593,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.euroneuro.2023.03.012","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T14:00:12Z","timestamp":1682085612000},"page":"60-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations"],"prefix":"10.1016","volume":"72","author":[{"given":"Flavia","family":"Rossano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Caiazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sobrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1749-2908","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Solini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4881-6004","authenticated-orcid":false,"given":"Nicolas","family":"Zotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-0853","authenticated-orcid":false,"given":"Michele","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8277-3397","authenticated-orcid":false,"given":"Ken","family":"Gillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-8105","authenticated-orcid":false,"given":"Carlo Ignazio","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-0054","authenticated-orcid":false,"given":"Vincent","family":"Van den Eynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom K.","family":"Birkenhager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6072-0358","authenticated-orcid":false,"given":"Henricus G.","family":"Ruh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-6973","authenticated-orcid":false,"given":"Stephen","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-5013","authenticated-orcid":false,"given":"Felice","family":"Iasevoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"de Bartolomeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2023.03.012_bib0001","unstructured":"Administration, F.a.D., 2006. FDA approves Emsam (selegiline) as first drug patch for depression [online]."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0002","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0278-5846(03)00117-9","article-title":"Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial","volume":"27","author":"Akhondzadeh","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hup.902","article-title":"Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study","volume":"23","author":"Amiri","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4088\/JCP.v64n0216","article-title":"A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder","volume":"64","author":"Amsterdam","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0005","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01.jcp.0000239794.37073.70","article-title":"Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial","volume":"26","author":"Amsterdam","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0006","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jad.2005.06.011","article-title":"MAOI efficacy and safety in advanced stage treatment-resistant depression\u2013a retrospective study","volume":"89","author":"Amsterdam","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0007","unstructured":"Association, A.P., 2022. Diagnostic and statistical manual of mental disorders (5th ed., text rev.)."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0008","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/0091270007302950","article-title":"Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers","volume":"47","author":"Azzaro","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0009","doi-asserted-by":"crossref","first-page":"d3371","DOI":"10.1136\/bmj.d3371","article-title":"Do antidepressants improve negative symptoms in schizophrenia?","volume":"342","author":"Barnes","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.pharmtox.48.113006.094742","article-title":"Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics","volume":"49","author":"Benowitz","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0011","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1046\/j.1360-0443.2003.00524.x","article-title":"A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation","volume":"98","author":"Biberman","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0012","article-title":"Cholinesterase und mono-aminoxydase im zentralen nervensystem","author":"Birkh\u00e4user","year":"1941","journal-title":"Schwabe"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0013","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01249880","article-title":"l-deprenyl plus l-phenylalanine in the treatment of depression","volume":"59","author":"Birkmayer","year":"1984","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852900020496","article-title":"Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6mg\/24 hour","volume":"12","author":"Blob","year":"2007","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0015","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","article-title":"Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients","volume":"159","author":"Bodkin","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0016","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00005053-199605000-00005","article-title":"Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine","volume":"184","author":"Bodkin","year":"1996","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0017","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.162.2.388","article-title":"Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia","volume":"162","author":"Bodkin","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0018","article-title":"Effects of selegiline on negative symptoms in schizophrenia","volume":"23","author":"Bordbar","year":"2008","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0019","series-title":"Irreversible Inhibition of Monoamine Oxidase B by the Antiparkinsonian Medicines Rasagiline and selegiline: a Computational Study","author":"Bor\u0161tnar","year":"2011"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/j.1552-4604.1989.tb03376.x","article-title":"The monoamine oxidase inhibitor-tyramine interaction","volume":"29","author":"Brown","year":"1989","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0021","article-title":"Clinical-Experience with l-Deprenyl in Endogenous-Depression","volume":"28","author":"Ceskova","year":"1986","journal-title":"Act. Nerv. Super. (Praha)"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0022","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0023","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/mds.21646","article-title":"Sialorrhea in Parkinson's disease: a review","volume":"22","author":"Chou","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0024","doi-asserted-by":"crossref","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0025","first-page":"243S","article-title":"Tolerability and effectiveness of the selegiline transdermal system (STS) in children and adolescents with attention deficit hyperactivity disorder (ADHD)","volume":"65","author":"Croarkin","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0026","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/cap.2013.0138","article-title":"A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents","volume":"24","author":"DelBello","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0027","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2006.04.010","article-title":"Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence","volume":"85","author":"Elkashef","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0028","first-page":"327","article-title":"Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety","volume":"32","author":"Ernst","year":"1996","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0029","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.4088\/JCP.v67n0905","article-title":"Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial","volume":"67","author":"Feiger","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0030","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1212\/WNL.46.4.965","article-title":"A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder","volume":"46","author":"Feigin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0031","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0028-3908(83)90194-6","article-title":"Selective MAO A and B inhibitors: their mechanism of action and pharmacology","volume":"22","author":"Finberg","year":"1983","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0032","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1345\/aph.1H556","article-title":"The role of selegiline in the treatment of negative symptoms associated with schizophrenia","volume":"41","author":"Fohey","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0033","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/npp.2014.214","article-title":"Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain","volume":"40","author":"Fowler","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0034","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0006-3223(02)01454-3","article-title":"A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation","volume":"53","author":"George","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0035","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1017\/S1092852919001196","article-title":"Revitalizing monoamine oxidase inhibitors: a call for action","volume":"25","author":"Gillman","year":"2020","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0036","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/0006-3223(93)90119-X","article-title":"A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia","volume":"33","author":"Goff","year":"1993","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0037","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00002018-199819010-00002","article-title":"Safety of selegiline (deprenyl) in the treatment of Parkinson's disease","volume":"19","author":"Heinonen","year":"1998","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0038","first-page":"93","article-title":"Pharmacokinetics and metabolism of selegiline","volume":"126","author":"Heinonen","year":"1989","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0039","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.psychres.2005.07.012","article-title":"Treatment of depression with atypical features: a meta-analytic approach","volume":"141","author":"Henkel","year":"2006","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0040","series-title":"Cochrane Handbook For Systematic Reviews of Interventions Version 6.3 (updated February 2022)","author":"Higgins","year":"2022"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0041","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00213-002-1152-9","article-title":"Effects of selegiline (L-deprenyl) during smoking and short-term abstinence","volume":"163","author":"Houtsmuller","year":"2002","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0042","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archneur.1993.00540030052014","article-title":"Deprenyl in attention deficit associated with Tourette's syndrome","volume":"50","author":"Jankovic","year":"1993","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0043","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/0006-2952(68)90066-X","article-title":"Some observations upon a new inhibitor of monoamine oxidase in brain tissue","volume":"17","author":"Johnston","year":"1968","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0044","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00004714-199912000-00006","article-title":"Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study","volume":"19","author":"Jungerman","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/ntr\/ntr143","article-title":"Selegiline transdermal system (STS) as an aid for smoking cessation","volume":"14","author":"Kahn","year":"2012","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0046","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jad.2019.03.028","article-title":"Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression","volume":"250","author":"Kim","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0047","series-title":"Do MAO-B Inhibitors Have Any Role in the Treatment of depression?, Inhibitors of Monoamine Oxidase B","first-page":"319","author":"Laux","year":"1993"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0048","article-title":"Clinical observation of selegiline in the treatment of post-stroke depression","author":"Li","year":"2008","journal-title":"Zhongguo Wuzhenxue Zazhi"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0049","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archpsyc.1984.01790180039005","article-title":"Phenelzine v imipramine in atypical depression. A preliminary report","volume":"41","author":"Liebowitz","year":"1984","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0050","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/0024-3205(80)90350-1","article-title":"l-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression","volume":"26","author":"Mann","year":"1980","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0051","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archpsyc.1989.01810010047007","article-title":"A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor","volume":"46","author":"Mann","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0052","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00004714-198202000-00008","article-title":"The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression","volume":"2","author":"Mann","year":"1982","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0053","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0920-9964(92)90019-2","article-title":"Platelet monoamine oxidase in schizophrenia: a meta-analysis","volume":"7","author":"Marcolin","year":"1992","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0054","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1046\/j.1471-4159.2002.00820.x","article-title":"Dopamine transport function is elevated in cocaine users","volume":"81","author":"Mash","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0055","first-page":"63","article-title":"A placebo-controlled trial of l-deprenyl in atypical depression","volume":"25","author":"McGrath","year":"1989","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0056","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00431109","article-title":"Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?","volume":"73","author":"Mendis","year":"1981","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0057","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0165-0327(80)90013-0","article-title":"Antidepressant potentiation of 5-hydroxytryptophan by l-deprenil in affective illness","volume":"2","author":"Mendlewicz","year":"1980","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0058","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1192\/bjp.142.5.508","article-title":"l-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation","volume":"142","author":"Mendlewicz","year":"1983","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0059","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1089\/cap.2004.14.418","article-title":"Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial","volume":"14","author":"Mohammadi","year":"2004","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0060","series-title":"Selegiline, StatPearls. StatPearls Publishing Copyright \u00a9 2022","author":"Moore","year":"2022"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0062","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1248\/bpb.29.2362","article-title":"Substrate selectivity of monoamine oxidase A, monoamine oxidase B, diamine oxidase, and semicarbazide-sensitive amine oxidase in COS-1 expression systems","volume":"29","author":"Ochiai","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0063","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/jrsm.1053","article-title":"GOSH\u2013a graphical display of study heterogeneity","volume":"3","author":"Olkin","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0064","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0165-1781(92)90082-E","article-title":"l-deprenyl in treating negative symptoms of schizophrenia","volume":"42","author":"Perenyi","year":"1992","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0066","first-page":"94","article-title":"Depression with atypical features: diagnostic validity, prevalence, and treatment","volume":"4","author":"Quitkin","year":"2002","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0067","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archpsyc.1984.01790190051006","article-title":"l-Deprenyl in atypical depressives","volume":"41","author":"Quitkin","year":"1984","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/S0009-9236(03)90458-9","article-title":"Pharmacokinetics (PK) effectiveness (E) and tolerability (T) of transdermal selegiline (STS) in children (C) and adolescents (A) with attention deficit hyperactivity disorder (ADHD)","volume":"73","author":"Reed","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0069","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0070","first-page":"124","article-title":"Monoamine oxidase inhibitors: a new generation","volume":"36","author":"Robinson","year":"2002","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0071","first-page":"15","article-title":"Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials","volume":"40","author":"Robinson","year":"2007","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0072","unstructured":"Rohatgi, A., 2017. WebPlotDigitizer. Austin, Texas, USA."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0073","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1089\/cap.2006.16.404","article-title":"Placebo-controlled study examining effects of selegiline in children with attention-deficit\/hyperactivity disorder","volume":"16","author":"Rubinstein","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0074","first-page":"137","article-title":"Rapid treatment of depression with selegiline-phenylalanine combination","volume":"52","author":"Sabelli","year":"1991","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0075","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/ntr\/ntu273","article-title":"Response to transdermal selegiline smoking cessation therapy and markers in the 15q24 chromosomal region","volume":"17","author":"Sarginson","year":"2015","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0076","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/clpt.1989.181","article-title":"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline","volume":"46","author":"Schulz","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0077","unstructured":"Sch\u00fcnemann, H., Bro\u017cek, J., Guyatt, G., Oxman, A., eds., 2013. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0078","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1520-6394(1998)7:3<126::AID-DA5>3.0.CO;2-9","article-title":"Low dose selegiline (L-Deprenyl) in social phobia","volume":"7","author":"Simpson","year":"1998","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0079","series-title":"EMSAM (r) Selegiline Transdermal System","author":"Somerset Pharmaceuticals","year":"2006"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0080","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ajodo.2019.12.011","article-title":"Prediction interval in random-effects meta-analysis","volume":"157","author":"Spineli","year":"2020","journal-title":"Am. J. Orthod. Dentofacial Orthop."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0081","series-title":"149th annual meeting of the american psychiatric association","article-title":"Selegiline for Negative Symptoms and Tardive Dyskinesia","author":"Stearns","year":"1996"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0082","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0083","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised crossover trials","volume":"366","author":"Sterne","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0084","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0085","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jad.2021.01.021","article-title":"Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: a systematic review and network meta-analysis","volume":"282","author":"Suchting","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0086","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archpsyc.1994.03950080019003","article-title":"High-dose selegiline in treatment-resistant older depressive patients","volume":"51","author":"Sunderland","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0087","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF00427904","article-title":"Tyramine pressor sensitivity changes during deprenyl treatment","volume":"86","author":"Sunderland","year":"1985","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0088","series-title":"RStudio: Integrated Development For R. RStudio","author":"Team","year":"2020"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0089","series-title":"R: A language and Environment For Statistical Computing","author":"Team","year":"2021"},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0090","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.2183\/pjab1945.44.1078","article-title":"Studies on the regional distribution of the monoamine oxidase activity in the brains of schizophrenic patients","volume":"44","author":"Utena","year":"1968","journal-title":"Proc. Jpn. Acad."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0091","first-page":"1","article-title":"The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression","author":"Van den Eynde","year":"2022","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0092","first-page":"1","article-title":"Classic monoamine oxidase inhibitors for depression: update on nursing care","author":"Van den Eynde","year":"2022","journal-title":"Issues Ment. Health Nurs."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0093","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0094","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2009.10.009","article-title":"A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers","volume":"107","author":"Weinberger","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0095","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s12035-012-8278-5","article-title":"Role of dopamine receptors in ADHD: a systematic meta-analysis","volume":"45","author":"Wu","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0096","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/clpt.1994.202","article-title":"Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors","volume":"56","author":"Youdim","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0097","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.euroneuro.2022.01.002","article-title":"Neuroscience-based nomenclature of psychotropics: progress report","volume":"57","author":"Zohar","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.012_bib0098","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:06:38Z","timestamp":1760378798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X23000627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":97,"alternative-id":["S0924977X23000627"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.03.012","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}